These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 18297617)

  • 1. [Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs].
    Vilalta-Franch J; Lopez-Pousa S; Garre-Olmo J; Turon-Estrada A; Pericot-Nierga I
    Rev Neurol; 2008 Feb 1-15; 46(3):129-34. PubMed ID: 18297617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
    Gareri P; Cotroneo A; Lacava R; Seminara G; Marigliano N; Loiacono A; De Sarro G
    Arch Gerontol Geriatr Suppl; 2004; (9):207-15. PubMed ID: 15207416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
    Layton D; Harris S; Wilton LV; Shakir SA
    J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
    Bret P; Bonnet F; Bret MC; Jaffré A
    Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antidepressant effects of risperidone and olanzapine in bipolar disorder.
    McIntyre RS; Mancini DA; Srinivasan J; McCann S; Konarski JZ; Kennedy SH
    Can J Clin Pharmacol; 2004; 11(2):e218-26. PubMed ID: 15520475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?
    Shah A
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):140-6. PubMed ID: 16416461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H; Slyk MP; Deymann S; Cornacchione MJ
    J Am Med Dir Assoc; 2003; 4(4):183-8. PubMed ID: 12837138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
    Madhusoodanan S; Bogunovic O
    CNS Spectr; 2007 Jan; 12(1):46-50. PubMed ID: 17192763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
    Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.
    Yin Y; Liu Y; Zhuang J; Pan X; Li P; Yang Y; Li YP; Zhao ZQ; Huang LQ; Zhao ZX
    Pharmacology; 2015; 96(3-4):155-62. PubMed ID: 26279176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
    Suh GH; Shah A
    Int Psychogeriatr; 2005 Sep; 17(3):429-41. PubMed ID: 16252375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.
    Gurpegui M; Alvarez E; Bousoño M; Ciudad A; Carlos Gómez J; Olivares JM
    Eur Neuropsychopharmacol; 2007 Nov; 17(11):725-34. PubMed ID: 17543505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic syndrome in Alzheimer's disease: clinical and developmental influences].
    Vilalta-Franch J; López-Pousa S; Garre-Olmo J; Turón-Estrada A; Pericot-Nierga I
    Rev Neurol; 2008 Jan 1-15; 46(1):13-7. PubMed ID: 18214821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.